Ferrari Cristina, Maggialetti Nicola, Masi Tamara, Nappi Anna Giulia, Santo Giulia, Niccoli Asabella Artor, Rubini Giuseppe
Section of Nuclear Medicine, DIM, University Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Section of Radiodiagnostic, DSMBNOS, University Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.
J Pers Med. 2021 Mar 18;11(3):217. doi: 10.3390/jpm11030217.
Immunotherapy is a promising therapeutic strategy both for solid and hematologic tumors, such as in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). In particular, immune-checkpoint inhibitors, such as nivolumab and pembrolizumab, are increasingly used for the treatment of refractory/relapsed HL. At the same time, evidence of chimeric antigen receptor (CAR)-T-cell immunotherapy efficacy mostly in NHL is growing. In this setting, the challenge is to identify an appropriate imaging method to evaluate immunotherapy response. The role of 18F-Fluorodeoxyglucose (18F-FDG) positron-emission tomography/computed tomography (PET/CT), especially in early evaluation, is under investigation in order to guide therapeutic strategies, taking into account the possible atypical responses (hyperprogression and pseudoprogression) and immune-related adverse events that could appear on PET images. Herein, we aimed to present a critical overview about the role of 18F-FDG PET/CT in evaluating treatment response to immunotherapy in lymphoma patients.
免疫疗法对于实体瘤和血液系统肿瘤，如霍奇金淋巴瘤（HL）和非霍奇金淋巴瘤（NHL）而言，是一种很有前景的治疗策略。特别是免疫检查点抑制剂，如纳武单抗和派姆单抗，越来越多地用于治疗难治性/复发性HL。与此同时，嵌合抗原受体（CAR）-T细胞免疫疗法主要在NHL中的疗效证据也越来越多。在这种情况下，挑战在于确定一种合适的成像方法来评估免疫疗法的反应。18F-氟脱氧葡萄糖（18F-FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）的作用，尤其是在早期评估中的作用，正在研究中，以便指导治疗策略，同时考虑到PET图像上可能出现的非典型反应（超进展和假性进展）以及免疫相关不良事件。在此，我们旨在对18F-FDG PET/CT在评估淋巴瘤患者免疫疗法治疗反应中的作用进行批判性综述。
